Sanaa Tejani1, Cody McCoy2, Colby R Ayers2, Tiffany M Powell-Wiley3, Jean-Pierre Després4, Jennifer Linge5, Olof Dahlqvist Leinhard6, Mikael Petersson7, Magnus Borga8, Ian J Neeland9. 1. University of Texas Southwestern Medical School, Dallas, TX. 2. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. 3. Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Intramural Research Program, National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD. 4. Department of Kinesiology, Faculty of Medicine, Université Laval and VITAM - Centre de rercherche en santé durable, CIUSSS Capitale-Nationale, Québec, QC, Canada. 5. AMRA Medical AB, Linköping, Sweden; Division of Society and Health, Linköping University, Linköping, Sweden. 6. AMRA Medical AB, Linköping, Sweden; Division of Diagnostics and Specialist Medicine, Linköping University, Linköping, Sweden; Department of Health, Medicine, and Caring Sciences, Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden. 7. AMRA Medical AB, Linköping, Sweden. 8. AMRA Medical AB, Linköping, Sweden; Department of Health, Medicine, and Caring Sciences, Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden; Division of Biomedical Engineering, Department of Biomedical Engineering, Linköping University, Linköping, Sweden. 9. University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH. Electronic address: ian.neeland@uhhospitals.org.
Abstract
OBJECTIVE: To evaluate the cardiometabolic outcomes associated with discordant visceral adipose tissue (VAT) and liver fat (LF) phenotypes in 2 cohorts. PATIENTS AND METHODS: Participants in the Dallas Heart Study underwent baseline imaging from January 1, 2000, through December 31, 2002, and were followed for incident cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) through 2013. Associations between VAT-LF groups (low-low, high-low, low-high, and high-high) and outcomes were assessed using multivariable-adjusted regression and were replicated in the independent UK Biobank. RESULTS: The Dallas Heart Study included 2064 participants (mean ± SD age, 44±9 years; 54% female; 47% black). High VAT-high LF and high VAT-low LF were associated with prevalent atherosclerosis, whereas low VAT-high LF was not. Of 1731 participants without CVD/T2DM, 128 (7.4%) developed CVD and 95 (5.5%) T2DM over a median of 12 years. High VAT-high LF and high VAT-low LF were associated with increased risk of CVD (hazard ratios [HRs], 2.0 [95% CI, 1.3 to 3.2] and 2.4 [95% CI, 1.4 to 4.1], respectively) and T2DM (odds ratios [ORs], 7.8 [95% CI, 3.8 to 15.8] and 3.3 [95% CI, 1.4 to 7.8], respectively), whereas low VAT-high LF was associated with T2DM (OR, 2.7 [95% CI, 1.1 to 6.7]). In the UK Biobank (N=22,354; April 2014-May 2020), only high VAT-low LF remained associated with CVD after multivariable adjustment for age and body mass index (HR, 1.5 [95% CI, 1.2 to 1.9]). CONCLUSION: Although VAT and LF are each associated with cardiometabolic risk, these observations demonstrate the importance of separating their cardiometabolic implications when there is presence or absence of either or both in an individual.
OBJECTIVE: To evaluate the cardiometabolic outcomes associated with discordant visceral adipose tissue (VAT) and liver fat (LF) phenotypes in 2 cohorts. PATIENTS AND METHODS: Participants in the Dallas Heart Study underwent baseline imaging from January 1, 2000, through December 31, 2002, and were followed for incident cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) through 2013. Associations between VAT-LF groups (low-low, high-low, low-high, and high-high) and outcomes were assessed using multivariable-adjusted regression and were replicated in the independent UK Biobank. RESULTS: The Dallas Heart Study included 2064 participants (mean ± SD age, 44±9 years; 54% female; 47% black). High VAT-high LF and high VAT-low LF were associated with prevalent atherosclerosis, whereas low VAT-high LF was not. Of 1731 participants without CVD/T2DM, 128 (7.4%) developed CVD and 95 (5.5%) T2DM over a median of 12 years. High VAT-high LF and high VAT-low LF were associated with increased risk of CVD (hazard ratios [HRs], 2.0 [95% CI, 1.3 to 3.2] and 2.4 [95% CI, 1.4 to 4.1], respectively) and T2DM (odds ratios [ORs], 7.8 [95% CI, 3.8 to 15.8] and 3.3 [95% CI, 1.4 to 7.8], respectively), whereas low VAT-high LF was associated with T2DM (OR, 2.7 [95% CI, 1.1 to 6.7]). In the UK Biobank (N=22,354; April 2014-May 2020), only high VAT-low LF remained associated with CVD after multivariable adjustment for age and body mass index (HR, 1.5 [95% CI, 1.2 to 1.9]). CONCLUSION: Although VAT and LF are each associated with cardiometabolic risk, these observations demonstrate the importance of separating their cardiometabolic implications when there is presence or absence of either or both in an individual.
Authors: A S Levey; S Adler; A W Caggiula; B K England; T Greene; L G Hunsicker; J W Kusek; N L Rogers; P E Teschan Journal: Am J Kidney Dis Date: 1996-05 Impact factor: 8.860
Authors: Magnus Borga; André Ahlgren; Thobias Romu; Per Widholm; Olof Dahlqvist Leinhard; Janne West Journal: Magn Reson Med Date: 2020-06-10 Impact factor: 4.668
Authors: Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs Journal: Hepatology Date: 2004-12 Impact factor: 17.425
Authors: Magnus Borga; E Louise Thomas; Thobias Romu; Johannes Rosander; Julie Fitzpatrick; Olof Dahlqvist Leinhard; Jimmy D Bell Journal: NMR Biomed Date: 2015-11-02 Impact factor: 4.044
Authors: Ian J Neeland; Colby R Ayers; Anand K Rohatgi; Aslan T Turer; Jarett D Berry; Sandeep R Das; Gloria L Vega; Amit Khera; Darren K McGuire; Scott M Grundy; James A de Lemos Journal: Obesity (Silver Spring) Date: 2013-05-19 Impact factor: 5.002
Authors: Janne West; Olof Dahlqvist Leinhard; Thobias Romu; Rory Collins; Steve Garratt; Jimmy D Bell; Magnus Borga; Louise Thomas Journal: PLoS One Date: 2016-09-23 Impact factor: 3.240
Authors: Hans Lennart Persson; Apostolos Sioutas; Magnus Kentson; Petra Jacobson; Peter Lundberg; Olof Dahlqvist Leinhard; Mikael Fredrik Forsgren Journal: J Inflamm Res Date: 2022-08-01
Authors: Björn Gerdle; Olof Dahlqvist Leinhard; Eva Lund; Ann Bengtsson; Peter Lundberg; Bijar Ghafouri; Mikael Fredrik Forsgren Journal: J Pain Res Date: 2022-08-27 Impact factor: 2.832